A Phase 1 interventional study of Insulin Lispro and Regular Human Insulin in Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-22.
Sponsored by Halozyme Therapeutics · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 1,995th largest by enrollment of the 2,501 interventional ones that give a count, is one of 163 that started in 2009, is one of 204 in phase 1, and was the 806th registered.
8,292 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 16–20
Mayo Clinic · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,022 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 262 · Phase 2 371 · Phase 3 340 · Phase 4 215
First in 1976; this study’s year is marked. 163 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 82 across the 2,501 interventional studies, 159 across the 499 observational. Of the 2,397 that completed or were terminated, 990 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
852 of 3,022 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 3 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
139 of the studies in Diabetes Mellitus with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Insulin lispro and regular human insulin are Food and Drug Administration (FDA)-approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with both insulin lispro and regular human insulin in order to determine if it improves the absorption of these insulins to more closely mimic the body's natural increase in insulin in response to a meal.
The purpose of this study is to compare the pharmacokinetics (absorption, distribution, breakdown and elimination) of regular human insulin + recombinant human hyaluronidase (rHuPH20) versus insulin lispro alone, and to compare the pharmacokinetics of insulin lispro + rHuPH20 versus insulin lispro alone. The effects of regular human insulin + rHuPH20, insulin lispro + rHuPH20, and insulin lispro alone on the body will be evaluated by blood glucose measurements and by calculating the rate at which a glucose solution is infused to maintain blood glucose within a certain range. The safety and tolerability of insulin lispro with and without rHuPH20 and regular human insulin with rHuPH20 will be studied. The study drugs will be administered by subcutaneous (under the skin) injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20) Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20 Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone There was a washout period of 3 to 14 days between interventions. The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections.
Drug: Insulin Lispro · Drug: Regular Human Insulin · Drug: rHuPH20
Also known as: Humalog
Also known as: RHI, Humulin R
Also known as: recombinant human hyaluronidase, HYLENEX
Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T])
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); and every 5 mins (from 15 to 30 mins) after each injection. The percent coefficient of variation (CV%) was calculated as 100\*(standard deviation/mean). The intra-participant CV% was calculated directly from the 2 replications of each treatment. The CV% for percentage of total AUC is reported from 0 to 30 minutes.
Time frame: predose up to 30 minutes postdose
Time to Early and Late 50% Maximum Serum Insulin Concentration (t[50%Max])
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
Time frame: predose up to 480 minutes postdose
Peak Serum Insulin Concentration (Cmax)
Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
Time frame: predose up to 480 minutes postdose
Time to Percentage of Total Glucose Infused
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection. Time to 25%, 50%, and 75% of total glucose infused are summarized.
Time frame: predose up to 480 minutes postdose
Percentage of Total Glucose Infused
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); and every 30 mins (from 90 to 240 mins) after each injection. Percentage of total glucose infused from 0 to 4 hours is summarized.
Time frame: predose up to 240 minutes postdose
Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
The number of TEAEs related to study drug (as determined by the Investigator) are summarized. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: first dose through 7 to 10 days after last dose
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 5 | 3 | 4 | 4 | 3 |
| Received at least one dose of study drug | 3 | 5 | 3 | 4 | 4 | 3 |
| Completed | 3 | 5 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 5 | 3 | 4 | 4 | 3 |
| Completed | 3 | 4 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 4 | 4 | 3 |
| Completed | 3 | 4 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lispro+rHuPH20 First, Then RHI+rHuPH20, Then Lispro Alone | Lispro+rHuPH20 First, Then Lispro Alone, Then RHI+rHuPH20 | RHI+rHuPH20 First, Then Lispro+rHuPH20, Then Lispro Alone | RHI+rHuPH20 First, Then Lispro Alone, Then Lispro+rHuPH20 | Lispro Alone First, Then Lispro+rHuPH20, Then RHI+rHuPH20 | Lispro Alone First, Then RHI+rHuPH20, Then Lispro+rHuPH20 |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 | 4 | 3 |
| Completed | 3 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); and every 5 mins (from 15 to 30 mins) after each injection. The percent coefficient of variation (CV%) was calculated as 100\*(standard deviation/mean). The intra-participant CV% was calculated directly from the 2 replications of each treatment. The CV% for percentage of total AUC is reported from 0 to 30 minutes.
| percentage of coefficient of variance | Insulin Lispro + rHuPH20 | Regular Human Insulin + rHuPH20 | Insulin Lispro Alone |
|---|---|---|---|
| Intra-participant Variability in Percent of Total Area Under the Plasma Insulin Concentration-Versus-Time Curve Attained by Time T (%AUC[0-T]) | 14.04 ± 11.12 | 23.81 ± 12.43 | 40.51 ± 24.30 |
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
| minutes | Insulin Lispro + rHuPH20 | Regular Human Insulin + rHuPH20 | Insulin Lispro Alone |
|---|---|---|---|
| early t(50%max) | 14.14 ± 3.01 | 21.52 ± 4.95 | 24.73 ± 5.16 |
| late t(50%max) | 88.14 ± 16.96 | 136.67 ± 27.16 | 144.43 ± 31.79 |
Cmax was determined as the maximum of all valid serum insulin concentration measurements for each measurement series. Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection.
| picomoles per liter (pmol/L) | Insulin Lispro + rHuPH20 | Regular Human Insulin + rHuPH20 | Insulin Lispro Alone |
|---|---|---|---|
| Peak Serum Insulin Concentration (Cmax) | 782.85 ± 199.84 | 561.93 ± 141.88 | 482.40 ± 119.50 |
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); every 30 mins (from 90 to 240 mins); and every 60 mins (from 240 to 480 mins) after each injection. Time to 25%, 50%, and 75% of total glucose infused are summarized.
| minutes | Insulin Lispro + rHuPH20 | Regular Human Insulin + rHuPH20 | Insulin Lispro Alone |
|---|---|---|---|
| 25% | 72.38 ± 12.50 | 91.58 ± 15.85 | 99.13 ± 19.26 |
| 50% | 118.95 ± 22.93 | 142.55 ± 21.31 | 156.83 ± 30.36 |
| 75% | 179.23 ± 40.73 | 203.15 ± 31.12 | 222.48 ± 44.44 |
Blood samples were taken 30, 20, 10 minutes (mins) prior to each injection; every 3 mins (from 0 to 15 mins); every 5 mins (from 15 to 30 mins); every 15 mins (from 30 to 90 mins); and every 30 mins (from 90 to 240 mins) after each injection. Percentage of total glucose infused from 0 to 4 hours is summarized.
| percentage of total glucose infused | Insulin Lispro + rHuPH20 | Regular Human Insulin + rHuPH20 | Insulin Lispro Alone |
|---|---|---|---|
| Percentage of Total Glucose Infused | 88.70 ± 9.04 | 85.17 ± 7.89 | 79.81 ± 11.27 |
The number of TEAEs related to study drug (as determined by the Investigator) are summarized. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events | Insulin Lispro + rHuPH20 | Regular Human Insulin + rHuPH20 | Insulin Lispro Alone |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) Related to Study Drug | 1 | 0 | 3 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Lispro + rHuPH20 | — | 0/22 (0%) | 4/22 (18.2%) |
| Regular Human Insulin + rHuPH20 | — | 0/20 (0%) | 4/20 (20%) |
| Insulin Lispro Alone | — | 0/21 (0%) | 9/21 (42.9%) |
| Event | Insulin Lispro + rHuPH20 | Regular Human Insulin + rHuPH20 | Insulin Lispro Alone |
|---|---|---|---|
| Catheter site painGeneral disorders | 2/22 | 1/20 | 2/21 |
| Injection site haemorrhageGeneral disorders | 0/22 | 0/20 | 2/21 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/22 | 1/20 | 0/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/22 | 1/20 | 1/21 |
| HeadacheNervous system disorders | 0/22 | 1/20 | 1/21 |
| VomitingGastrointestinal disorders | 0/22 | 0/20 | 1/21 |
| Injection site irritationGeneral disorders | 0/22 | 0/20 | 1/21 |
| Upper respiratory tract infectionInfections and infestations | 1/22 | 0/20 | 1/21 |
| Thermal burnInjury, poisoning and procedural complications | 0/22 | 0/20 | 1/21 |
| Flank painMusculoskeletal and connective tissue disorders | 0/22 | 0/20 | 1/21 |
Participants who received at least one dose of insulin lispro, regular human insulin, or recombinant human hyaluronidase (rHuPH20).
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 35.9 ± 9.24 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 10 |
| Male | 12 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 17 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | All Participants |
|---|---|
| United States | 22 |
The record gives a start of Mar 2009, a primary completion of Jun 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)